Table 3. Summary of the most representative reports about HeartWare utilization in the setting of the BTT strategy.

Author (Ref.), study period	Patients (n.)	Mean support time (days)	Competing outcomes^a	Survival
Wieselthaler (24), 03/2006-11/2007	23	305	HTx 21%, ongoing 60%, recovery 4%, death 13%	6-month 91%, 12-month 86%
Strueber (20), 03/2006-12/2008	50	348	HTx 40%, ongoing 34%, recovery 8%, death 18%	6-month 90%, 12-month 84%, 24-month 79%
Aaronson (21), 08/2008-08/2010	140	249^b	HTx 28%, ongoing 62%, recovery 0%, death 4%	6-month 94%, 12-month 86%
Slaughter (22), 08/2008-12/2011	332	275^b	HTx + recovery 21%, ongoing 67%, death 6%	6-month 91%, 12-month 84%
Strueber (23), 02/2009-11/2012	254	363	HTx 22%, ongoing 59%, recovery 1%, death 16%	6-month 87%, 12-month 85%, 24-month 79%

^a, competing outcomes analysis must be reported to different follow-up periods (FUP): 12-month FUP (24), 12-month FUP (20), 6-month FUP (21), 6-month FUP (22); ^b, median support time; ^c, survival data are referred to as estimate of success (defined as survival to HTx, successful recovery with device explant or remaining on continued HeartWare support). BTT, bridge-to-transplantation; HTx, heart transplantation; NR, not reported.